Wafaa M El Sadr
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Wafaa M El Sadr has a total of 454 co-authors. Here are the top co-authors by number of shared publications:
- Alexander Kailembo
Division of Global HIV and TB, U.S. Centers for Diseases Control and Prevention, Dar es Salaam, Tanzania
4 shared publications Miriam Rabkin
ICAP at Columbia University, New York, NY, USA
4 shared publications- Abbas Kihame Ismail
Division of Global HIV and TB, U.S. Centers for Diseases Control and Prevention, Dar es Salaam, Tanzania
3 shared publications - Amanda Mocroft
Centre for Clinical Research, Epidemiology, Modelling and Evaluation, Institute for Global Health, University College London, London, United Kingdom
3 shared publications - Andrew C. Voetsch
Division of Global HIV and TB, Global Health Center, Centers for Disease Control and Prevention, USA
3 shared publications - Andrew N. Phillips
Institute for Global Health, University College London , London
3 shared publications
Latest Publications
- Open Access
- 8 August 2026
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 13 (9)
Population HIV Viremia and Epidemic Transition: Findings From Sequential Surveys in 6 Sub-Saharan African Countries
Background: Testing and treatment targets may not fully capture the progress of the epidemic. Whether cascade gains translate into short-term reductions in new infections, as reflected by the incidence-to-prevalence ratio (IPR), remains uncertain. Methods: We analyzed 2 rounds of Population-based HIV Impact Assessment surveys in Eswatini, Lesotho, Malawi, Tanzania, Uganda, and Zimbabwe (Round 1, 2015–2017; Round 2, 2019–2023) among adults aged 15–59 years. We estimated human immunodeficiency virus (HIV) prevalence, the 95–95–95 cascade, population viral load suppression (PVLS), population viremia (PV), HIV incidence, and IPR using survey-weighted methods. Population viremia was categorized as undiagnosed and viremic, diagnosed but not on antiretroviral therapy (ART), or on ART but not suppressed. Results: The sample included 113 970 Round 1 and 112 445 Round 2 participants. Across countries, PVLS ranged from 52.0% to 72.4% in Round 1 and from 74.5% to 88.0% in Round 2; PV ranged from 2.4% to 8.3% in Round 1 and from 1.0% to 4.7% in Round 2. In Round 2, undiagnosed infection accounted for most PV in 4 countries (53.1%–71.4%). Incidence estimates were lower in Round 2 in 5 countries, but CIs were wide and overlapping. The incidence-to-prevalence ratio ranged from 3.0% to 6.7% in Round 1 and from 2.1% to 5.1% in Round 2; estimates were <3% in Eswatini, Lesotho, and Malawi, but CIs included 3%. Conclusions: Population viral load suppression increased, and PV declined in all countries, but precision for short-term IPR change was limited. Residual viremia was concentrated among undiagnosed adults, supporting targeted testing, rapid linkage, and treatment continuity.
- 8 August 2026
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 13 (9)
Open AccessPopulation HIV Viremia and Epidemic Transition: Findings From Sequential Surveys in 6 Sub-Saharan African Countries
Background: Testing and treatment targets may not fully capture the progress of the epidemic. Whether cascade gains translate into short-term reductions in new infections, as reflected by the incidence-to-prevalence ratio (IPR), remains uncertain. Methods: We analyzed 2 rounds of Population-based HIV Impact Assessment surveys in Eswatini, Lesotho, Malawi, Tanzania, Uganda, and Zimbabwe (Round 1, 2015–2017; Round 2, 2019–2023) among adults aged 15–59 years. We estimated human immunodeficiency virus (HIV) prevalence, the 95–95–95 cascade, population viral load suppression (PVLS), population viremia (PV), HIV incidence, and IPR using survey-weighted methods. Population viremia was categorized as undiagnosed and viremic, diagnosed but not on antiretroviral therapy (ART), or on ART but not suppressed. Results: The sample included 113 970 Round 1 and 112 445 Round 2 participants. Across countries, PVLS ranged from 52.0% to 72.4% in Round 1 and from 74.5% to 88.0% in Round 2; PV ranged from 2.4% to 8.3% in Round 1 and from 1.0% to 4.7% in Round 2. In Round 2, undiagnosed infection accounted for most PV in 4 countries (53.1%–71.4%). Incidence estimates were lower in Round 2 in 5 countries, but CIs were wide and overlapping. The incidence-to-prevalence ratio ranged from 3.0% to 6.7% in Round 1 and from 2.1% to 5.1% in Round 2; estimates were <3% in Eswatini, Lesotho, and Malawi, but CIs included 3%. Conclusions: Population viral load suppression increased, and PV declined in all countries, but precision for short-term IPR change was limited. Residual viremia was concentrated among undiagnosed adults, supporting targeted testing, rapid linkage, and treatment continuity.
- 1 July 2026
- Published by Wolters Kluwer Health in JAIDS Journal of Acquired Immune Deficiency Syndromes
- Vol. 101 (7) , 733-739
Population Viral Load Suppression and Associated Factors in Tanzania: Findings From 2 Sequential Tanzania HIV Impact Surveys of 2016–2017 and 2022–2023
Background: Antiretroviral therapy improves outcomes for people living with HIV (PLHIV) and prevents transmission through viral load suppression (VLS). To evaluate progress toward HIV epidemic control, VLS prevalences and correlates among PLHIV were analyzed from Tanzania HIV Impact Assessment Surveys (THIS), independent, cross-sectional using stratified-cluster design, conducted in 2016–2017 (S1) and 2022–2023 (S2). Methods: Participants 15 years and older provided consent, completed an interviewer-administered questionnaire, and tested for HIV using the national rapid testing algorithm. HIV-positive specimens were tested for viral load. Prevalence of population VLS (P < 0.0001) between surveys. In both surveys, women were more likely to experience VLS [S1: 1.43 (95% CI: 1.25 to 1.63), S2: 1.15 (95% CI: 1.06 to 1.24)] than men. In both surveys, PLHIV 35 years and older were more likely to experience VLS than those 15–24 years, [S1 35–49 years: 1.46 (95% CI: 1.13 to 1.90), 50 years and older: 1.69 (95% CI: 1.28 to 2.23), and S2 35–49 years: 1.31 (95% CI: 1.06 to 1.62), 50 years and older: 1.42 (95% CI: 1.15 to 1.76)]. Conclusion: Tanzania has made progress toward HIV epidemic control, as evidenced by the significant increase in VLS prevalence in 6 years. Targeted sex–age strategies are essential for HIV epidemic control.
- 1 July 2026
- Published by Wolters Kluwer Health in JAIDS Journal of Acquired Immune Deficiency Syndromes
- Vol. 101 (7) , 733-739
Population Viral Load Suppression and Associated Factors in Tanzania: Findings From 2 Sequential Tanzania HIV Impact Surveys of 2016–2017 and 2022–2023
Background: Antiretroviral therapy improves outcomes for people living with HIV (PLHIV) and prevents transmission through viral load suppression (VLS). To evaluate progress toward HIV epidemic control, VLS prevalences and correlates among PLHIV were analyzed from Tanzania HIV Impact Assessment Surveys (THIS), independent, cross-sectional using stratified-cluster design, conducted in 2016–2017 (S1) and 2022–2023 (S2). Methods: Participants 15 years and older provided consent, completed an interviewer-administered questionnaire, and tested for HIV using the national rapid testing algorithm. HIV-positive specimens were tested for viral load. Prevalence of population VLS (P < 0.0001) between surveys. In both surveys, women were more likely to experience VLS [S1: 1.43 (95% CI: 1.25 to 1.63), S2: 1.15 (95% CI: 1.06 to 1.24)] than men. In both surveys, PLHIV 35 years and older were more likely to experience VLS than those 15–24 years, [S1 35–49 years: 1.46 (95% CI: 1.13 to 1.90), 50 years and older: 1.69 (95% CI: 1.28 to 2.23), and S2 35–49 years: 1.31 (95% CI: 1.06 to 1.62), 50 years and older: 1.42 (95% CI: 1.15 to 1.76)]. Conclusion: Tanzania has made progress toward HIV epidemic control, as evidenced by the significant increase in VLS prevalence in 6 years. Targeted sex–age strategies are essential for HIV epidemic control.
- Open Access
- 25 February 2026
- Published by Elsevier in SSRN Electronic Journal
Two Pathways to Unsuppressed Viral Load among Adults on Antiretroviral Therapy in Seven Sub-Saharan African Countries, 2019–2023: Virologic Failure Versus Treatment Interruption
Background: Achieving viral load suppression (VLS) among people with HIV on antiretroviral therapy (ART) remains a critical priority in sub-Saharan Africa. We aimed to determine the prevalence of virologic failure (VF) versus interruption in treatment (IIT) among adults with unsuppressed viral load using viral load testing combined with antiretroviral drug (ARV) detection.Methods: We analyzed Population-based HIV Impact Assessment (PHIA) survey data from seven sub-Saharan African countries (Eswatini, Lesotho, Malawi, Mozambique, Tanzania, Uganda, Zimbabwe) conducted during 2019–2023. Among participants aged ≥15 years with HIV who self-reported current ART use and ART initiation ≥4 months before the survey interview (n=14,834), we classified VLS (viral load <1,000 copies/mL), VF (viral load ≥1,000 copies/mL with detectable ARVs), and IIT (viral load ≥1,000 copies/mL without detectable ARVs). We examined adherence patterns and used survey-weighted Poisson regression to identify factors associated with VF and IIT.Findings: Overall VLS was 92.4% (95% CI 91.6–93.0), ranging from 89.4% in Mozambique to 96.9% in Malawi. Among all participants, 4.7% (95% CI 4.2–5.2) had VF and 3.0% (95% CI 2.5–3.5) had IIT. Younger adults (15–29 years) had significantly higher prevalence of both VF and IIT, with the strongest association observed for IIT (adjusted prevalence ratio [aPR] 7.61, 95% CI 4.47–12.97; vs ≥45 years). Men had significantly higher VF than women (aPR 1.62, 95% CI 1.20–2.18). Compared with dolutegravir-based regimens, efavirenz-based regimens (aPR 3.64, 95% CI 2.16–6.13) and nevirapine/atazanavir/lopinavir-based regimens (aPR 3.64, 95% CI 1.90–6.96) were each associated with VF. Suboptimal adherence was associated with VF (aPR 2.06, 95% CI 1.48–2.86) and IIT (aPR 1.78, 95% CI 1.16–2.75).Interpretation: In these seven sub-Saharan African countries, both VF and IIT were observed among people aged ≥15 years with unsuppressed viral load despite ART, with VF more common than IIT. Improving VLS may require complementary strategies to optimize ART regimens and strengthen adherence support, alongside efforts to prevent or rapidly reverse treatment interruptions, particularly among men and younger adults.
- 25 February 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessTwo Pathways to Unsuppressed Viral Load among Adults on Antiretroviral Therapy in Seven Sub-Saharan African Countries, 2019–2023: Virologic Failure Versus Treatment Interruption
Background: Achieving viral load suppression (VLS) among people with HIV on antiretroviral therapy (ART) remains a critical priority in sub-Saharan Africa. We aimed to determine the prevalence of virologic failure (VF) versus interruption in treatment (IIT) among adults with unsuppressed viral load using viral load testing combined with antiretroviral drug (ARV) detection.Methods: We analyzed Population-based HIV Impact Assessment (PHIA) survey data from seven sub-Saharan African countries (Eswatini, Lesotho, Malawi, Mozambique, Tanzania, Uganda, Zimbabwe) conducted during 2019–2023. Among participants aged ≥15 years with HIV who self-reported current ART use and ART initiation ≥4 months before the survey interview (n=14,834), we classified VLS (viral load <1,000 copies/mL), VF (viral load ≥1,000 copies/mL with detectable ARVs), and IIT (viral load ≥1,000 copies/mL without detectable ARVs). We examined adherence patterns and used survey-weighted Poisson regression to identify factors associated with VF and IIT.Findings: Overall VLS was 92.4% (95% CI 91.6–93.0), ranging from 89.4% in Mozambique to 96.9% in Malawi. Among all participants, 4.7% (95% CI 4.2–5.2) had VF and 3.0% (95% CI 2.5–3.5) had IIT. Younger adults (15–29 years) had significantly higher prevalence of both VF and IIT, with the strongest association observed for IIT (adjusted prevalence ratio [aPR] 7.61, 95% CI 4.47–12.97; vs ≥45 years). Men had significantly higher VF than women (aPR 1.62, 95% CI 1.20–2.18). Compared with dolutegravir-based regimens, efavirenz-based regimens (aPR 3.64, 95% CI 2.16–6.13) and nevirapine/atazanavir/lopinavir-based regimens (aPR 3.64, 95% CI 1.90–6.96) were each associated with VF. Suboptimal adherence was associated with VF (aPR 2.06, 95% CI 1.48–2.86) and IIT (aPR 1.78, 95% CI 1.16–2.75).Interpretation: In these seven sub-Saharan African countries, both VF and IIT were observed among people aged ≥15 years with unsuppressed viral load despite ART, with VF more common than IIT. Improving VLS may require complementary strategies to optimize ART regimens and strengthen adherence support, alongside efforts to prevent or rapidly reverse treatment interruptions, particularly among men and younger adults.
- Open Access
- 3 February 2026
- Published by Elsevier in SSRN Electronic Journal
Change in HIV Incidence, Prevalence and Population Viremia in Tanzania: Findings from Tanzania HIV Impact Surveys in 2016–2017 and 2022–2023
Background: Tanzania has over 1.5 million people living with HIV. Understanding changes in its HIV epidemic is critical to informing interventions and policies. We aim to describe the state of Tanzania’s HIV epidemic and progress towards epidemic control by evaluating changes in population-level HIV prevalence, HIV incidence, and viremia between 2016–2017 and 2022–2023. Methods: Sequential Tanzania HIV Impact Surveys (THIS) 2016–2017 and 2022–2023 were nationally-representative, cross-sectional household-based surveys with a stratified, two-stage cluster design. Participants aged ≥15 years provided information on HIV testing and treatment histories and blood samples for HIV serology. HIV incidence was estimated using a laboratory-based algorithm (HIV-1 Limiting Antigen (Lag) avidity, viral load (VL), and antiretroviral (ARV) detection). We calculated weighted estimates of population-level HIV prevalence, HIV incidence, and viremia and compared them between surveys. Arithmetic differences and incidence rate ratios were used to assess change. Modified Poisson regression models were used to estimate adjusted prevalence ratios (aPR) for correlates of HIV prevalence and viremia. Findings: Among participants aged ≥15 years with biomarker data (n=31,579 in 2016–2017; n=33,663 in 2022–2023), 1,831 and 1,850 were living with HIV, respectively. HIV prevalence remained stable at 4.9% [95% CI: 4.5–5.2] in 2016–2017 and 4.4% [4.1–4.7] in 2022–2023. Annual HIV incidence did not significantly change (0.24% [0.15–0.34] vs. 0.18% [0.09–0.26]). Population viremia declined significantly from 2.8% [2.6–3.1] to 1.7% [1.5–1.8], with a 41% reduction between surveys (aPR: 0.59 [0.52–0.67]). Higher prevalence and viremia were observed among women and adults aged ≥25 years. Interpretation: Between 2016–2017 and 2022–2023, HIV prevalence and incidence remained stable in Tanzania, while population viremia declined substantially, indicating progress towards HIV epidemic control. Continued efforts and targeted interventions are needed to reduce viremia among women and older age groups.
- 3 February 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessChange in HIV Incidence, Prevalence and Population Viremia in Tanzania: Findings from Tanzania HIV Impact Surveys in 2016–2017 and 2022–2023
Background: Tanzania has over 1.5 million people living with HIV. Understanding changes in its HIV epidemic is critical to informing interventions and policies. We aim to describe the state of Tanzania’s HIV epidemic and progress towards epidemic control by evaluating changes in population-level HIV prevalence, HIV incidence, and viremia between 2016–2017 and 2022–2023. Methods: Sequential Tanzania HIV Impact Surveys (THIS) 2016–2017 and 2022–2023 were nationally-representative, cross-sectional household-based surveys with a stratified, two-stage cluster design. Participants aged ≥15 years provided information on HIV testing and treatment histories and blood samples for HIV serology. HIV incidence was estimated using a laboratory-based algorithm (HIV-1 Limiting Antigen (Lag) avidity, viral load (VL), and antiretroviral (ARV) detection). We calculated weighted estimates of population-level HIV prevalence, HIV incidence, and viremia and compared them between surveys. Arithmetic differences and incidence rate ratios were used to assess change. Modified Poisson regression models were used to estimate adjusted prevalence ratios (aPR) for correlates of HIV prevalence and viremia. Findings: Among participants aged ≥15 years with biomarker data (n=31,579 in 2016–2017; n=33,663 in 2022–2023), 1,831 and 1,850 were living with HIV, respectively. HIV prevalence remained stable at 4.9% [95% CI: 4.5–5.2] in 2016–2017 and 4.4% [4.1–4.7] in 2022–2023. Annual HIV incidence did not significantly change (0.24% [0.15–0.34] vs. 0.18% [0.09–0.26]). Population viremia declined significantly from 2.8% [2.6–3.1] to 1.7% [1.5–1.8], with a 41% reduction between surveys (aPR: 0.59 [0.52–0.67]). Higher prevalence and viremia were observed among women and adults aged ≥25 years. Interpretation: Between 2016–2017 and 2022–2023, HIV prevalence and incidence remained stable in Tanzania, while population viremia declined substantially, indicating progress towards HIV epidemic control. Continued efforts and targeted interventions are needed to reduce viremia among women and older age groups.
- Open Access
- 3 February 2026
- Published by Elsevier in SSRN Electronic Journal
Progress Towards Global 95–95–95 Targets in Tanzania: Trends from Tanzania HIV Impact Surveys in 2016–2017 and 2022–2023
Background: The global 95–95–95 targets state that 95% of people living with HIV (PLHIV) are aware of their HIV status, 95% of those are taking antiretroviral therapy (ART), and 95% of those have HIV viral load (VL) suppression (VLS). We evaluated change in 95–95–95 achievement between two rounds of a national HIV survey in Tanzania. Methods: The Tanzania HIV Impact Surveys (THIS) in 2016–2017 and 2022–2023 were nationally-representative, cross-sectional household surveys. Consenting participants responded to a questionnaire and provided blood specimens for biomarker testing. We reported 95–95–95 achievement among PLHIV aged ≥15 years in each round and the change using prevalence differences. We determined awareness of status and ART use through both self-report and detection of ARVs in the blood. We defined HIV VLS as HIV VL <1,000 copies/mL. Analyses accounted for the complex survey design with pooled survey weights and Jackknife variance estimation. Findings: This analysis included 1,831 and 1,850 PLHIV aged ≥15 years from THIS 2016–2017 and THIS 2022–2023, respectively. PLHIV aware of HIV-positive status increased from 61.0% [57.1–63.9] in 2017 to 83.0% [80.0–85.1] in 2023; this was a prevalence difference of 22.1% [17.8–26.3]. Among PLHIV aware of their status, ART coverage increased from 93.6% [91.7–95.2] in 2017 to 97.9% [96.7–98.6] in 2023; this was a prevalence difference of 4.2% [2.3–6.2]. Among PLHIV on ART, the percent with VLS increased from 87.0% [84.1–89.5] in 2017 to 94.3% [92.6–95.6] in 2023; this was a prevalence difference of 7.2% [4.2–10.3]. Interpretation: Tanzania made remarkable progress towards all three 95–95–95 targets in the five years between surveys. Efforts are needed to enhance case identification through tailored strategies.
- 3 February 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessProgress Towards Global 95–95–95 Targets in Tanzania: Trends from Tanzania HIV Impact Surveys in 2016–2017 and 2022–2023
Background: The global 95–95–95 targets state that 95% of people living with HIV (PLHIV) are aware of their HIV status, 95% of those are taking antiretroviral therapy (ART), and 95% of those have HIV viral load (VL) suppression (VLS). We evaluated change in 95–95–95 achievement between two rounds of a national HIV survey in Tanzania. Methods: The Tanzania HIV Impact Surveys (THIS) in 2016–2017 and 2022–2023 were nationally-representative, cross-sectional household surveys. Consenting participants responded to a questionnaire and provided blood specimens for biomarker testing. We reported 95–95–95 achievement among PLHIV aged ≥15 years in each round and the change using prevalence differences. We determined awareness of status and ART use through both self-report and detection of ARVs in the blood. We defined HIV VLS as HIV VL <1,000 copies/mL. Analyses accounted for the complex survey design with pooled survey weights and Jackknife variance estimation. Findings: This analysis included 1,831 and 1,850 PLHIV aged ≥15 years from THIS 2016–2017 and THIS 2022–2023, respectively. PLHIV aware of HIV-positive status increased from 61.0% [57.1–63.9] in 2017 to 83.0% [80.0–85.1] in 2023; this was a prevalence difference of 22.1% [17.8–26.3]. Among PLHIV aware of their status, ART coverage increased from 93.6% [91.7–95.2] in 2017 to 97.9% [96.7–98.6] in 2023; this was a prevalence difference of 4.2% [2.3–6.2]. Among PLHIV on ART, the percent with VLS increased from 87.0% [84.1–89.5] in 2017 to 94.3% [92.6–95.6] in 2023; this was a prevalence difference of 7.2% [4.2–10.3]. Interpretation: Tanzania made remarkable progress towards all three 95–95–95 targets in the five years between surveys. Efforts are needed to enhance case identification through tailored strategies.
- Open Access
- 11 April 2025
- Published by International Society of Global Health in Journal of Global Health
- Vol. 15, 04114
Infectious disease forecasting to support public health: use of readily available methods to predict malaria and diarrhoeal diseases in Mozambique
Mozambique is one of the world’s least resourced nations, positioned at 185 out of 191 countries on the Human Development Index in 2021 [1]. The country grapples with numerous challenges, including weak infrastructure and limited access to clean water, sanitation, roads, and health facilities [2]. In addition, the country is persistently confronted with natural disasters, […]
- 11 April 2025
- Published by International Society of Global Health in Journal of Global Health
- Vol. 15, 04114
Open AccessInfectious disease forecasting to support public health: use of readily available methods to predict malaria and diarrhoeal diseases in Mozambique
Mozambique is one of the world’s least resourced nations, positioned at 185 out of 191 countries on the Human Development Index in 2021 [1]. The country grapples with numerous challenges, including weak infrastructure and limited access to clean water, sanitation, roads, and health facilities [2]. In addition, the country is persistently confronted with natural disasters, […]
- 10 November 2023
- Published by American Association for the Advancement of Science (AAAS) in Science
- Vol. 382 (6671) , 621
Global fight against HIV is at risk
- 10 November 2023
- Published by American Association for the Advancement of Science (AAAS) in Science
- Vol. 382 (6671) , 621
Global fight against HIV is at risk
- 1 July 2022
- Published by American Public Health Association in American Journal of Public Health
- Vol. 112 (7) , 1025-1033
Contact Tracing: Barriers and Facilitators
Contact tracing—the process of identifying, isolating, and managing infected persons and their contacts—is a recognized public health measure for controlling the transmission of infectious diseases. In the context of the COVID-19 pandemic, contact tracing has received intense attention. We provide a brief overview of the history of contact tracing during several major disease outbreaks in the past century: syphilis and other sexually transmitted infections, HIV infection, tuberculosis, Ebola virus disease, and COVID-19. Our discussion on the barriers to and facilitators of contact tracing offers a perspective on societal and institutional roles and dynamics, stigma as a major barrier to effective tracing efforts, and how the nature and epidemiology of the infection itself can affect its success. We explore the evolution and adaptation of contact tracing and provide insights for future programming and research. (Am J Public Health. 2022;112(7):1025–1033. https://doi.org/10.2105/AJPH.2022.306842 )
- 1 July 2022
- Published by American Public Health Association in American Journal of Public Health
- Vol. 112 (7) , 1025-1033
Contact Tracing: Barriers and Facilitators
Contact tracing—the process of identifying, isolating, and managing infected persons and their contacts—is a recognized public health measure for controlling the transmission of infectious diseases. In the context of the COVID-19 pandemic, contact tracing has received intense attention. We provide a brief overview of the history of contact tracing during several major disease outbreaks in the past century: syphilis and other sexually transmitted infections, HIV infection, tuberculosis, Ebola virus disease, and COVID-19. Our discussion on the barriers to and facilitators of contact tracing offers a perspective on societal and institutional roles and dynamics, stigma as a major barrier to effective tracing efforts, and how the nature and epidemiology of the infection itself can affect its success. We explore the evolution and adaptation of contact tracing and provide insights for future programming and research. (Am J Public Health. 2022;112(7):1025–1033. https://doi.org/10.2105/AJPH.2022.306842 )
- Open Access
- 7 June 2022
- Published by JMIR Publications Inc. in JMIR Public Health and Surveillance
- Vol. 8 (6) , e37479
Public Health Implications of Adapting HIV Pre-exposure Prophylaxis Programs for Virtual Service Delivery in the Context of the COVID-19 Pandemic: Systematic Review
Background: The novel coronavirus disease COVID-19 caused by SARS-CoV-2 threatens to disrupt global progress toward HIV epidemic control. Opportunities exist to leverage ongoing public health responses to mitigate the impacts of COVID-19 on HIV services, and novel approaches to care provision might help address both epidemics. Objective: As the COVID-19 pandemic continues, novel approaches to maintain comprehensive HIV prevention service delivery are needed. The aim of this study was to summarize the related literature to highlight adaptations that could address potential COVID-19–related service interruptions. Methods: We performed a systematic review and searched six databases, OVID/Medline, Scopus, Cochrane Library, CINAHL, PsycINFO, and Embase, for studies published between January 1, 2010, and October 26, 2021, related to recent technology-based interventions for virtual service delivery. Search terms included “telemedicine,” “telehealth,” “mobile health,” “eHealth,” “mHealth,” “telecommunication,” “social media,” “mobile device,” and “internet,” among others. Of the 6685 abstracts identified, 1259 focused on HIV virtual service delivery, 120 of which were relevant for HIV prevention efforts; 48 pertained to pre-exposure prophylaxis (PrEP) and 19 of these focused on evaluations of interventions for the virtual service delivery of PrEP. Of the 16 systematic reviews identified, three were specific to PrEP. All 35 papers were reviewed for outcomes of efficacy, feasibility, and/or acceptability. Limitations included heterogeneity of the studies’ methodological approaches and outcomes; thus, a meta-analysis was not performed. We considered the evidence-based interventions found in our review and developed a virtual service delivery model for HIV prevention interventions. We also considered how this platform could be leveraged for COVID-19 prevention and care. Results: We summarize 19 studies of virtual service delivery of PrEP and 16 relevant reviews. Examples of technology-based interventions that were effective, feasible, and/or acceptable for PrEP service delivery include: use of SMS, internet, and smartphone apps such as iText (50% [95% CI 16%-71%] reduction in discontinuation of PrEP) and PrEPmate (OR 2.62, 95% CI 1.24-5.5.4); telehealth and eHealth platforms for virtual visits such as PrEPTECH and IowaTelePrEP; and platforms for training of health care workers such as Extension for Community Healthcare Outcomes (ECHO). We suggest a virtual service delivery model for PrEP that can be leveraged for COVID-19 using the internet and social media for demand creation, community-based self-testing, telehealth platforms for risk assessment and follow-up, applications for support groups and adherence/appointment reminders, and applications for monitoring. Conclusions: Innovations in the virtual service provision of PrEP occurred before COVID-19 but have new relevance during the COVID-19 pandemic. The innovations we describe might strengthen HIV prevention service delivery during the COVID-19 pandemic and in the long run by engaging traditionally hard-to-reach populations, reducing stigma, and creating a more accessible health care platform. These virtual service delivery platforms can mitigate the impacts of the COVID-19 pandemic on HIV services, which can be leveraged to facilitate COVID-19 pandemic control now and for future responses.
- 7 June 2022
- Published by JMIR Publications Inc. in JMIR Public Health and Surveillance
- Vol. 8 (6) , e37479
Open AccessPublic Health Implications of Adapting HIV Pre-exposure Prophylaxis Programs for Virtual Service Delivery in the Context of the COVID-19 Pandemic: Systematic Review
Background: The novel coronavirus disease COVID-19 caused by SARS-CoV-2 threatens to disrupt global progress toward HIV epidemic control. Opportunities exist to leverage ongoing public health responses to mitigate the impacts of COVID-19 on HIV services, and novel approaches to care provision might help address both epidemics. Objective: As the COVID-19 pandemic continues, novel approaches to maintain comprehensive HIV prevention service delivery are needed. The aim of this study was to summarize the related literature to highlight adaptations that could address potential COVID-19–related service interruptions. Methods: We performed a systematic review and searched six databases, OVID/Medline, Scopus, Cochrane Library, CINAHL, PsycINFO, and Embase, for studies published between January 1, 2010, and October 26, 2021, related to recent technology-based interventions for virtual service delivery. Search terms included “telemedicine,” “telehealth,” “mobile health,” “eHealth,” “mHealth,” “telecommunication,” “social media,” “mobile device,” and “internet,” among others. Of the 6685 abstracts identified, 1259 focused on HIV virtual service delivery, 120 of which were relevant for HIV prevention efforts; 48 pertained to pre-exposure prophylaxis (PrEP) and 19 of these focused on evaluations of interventions for the virtual service delivery of PrEP. Of the 16 systematic reviews identified, three were specific to PrEP. All 35 papers were reviewed for outcomes of efficacy, feasibility, and/or acceptability. Limitations included heterogeneity of the studies’ methodological approaches and outcomes; thus, a meta-analysis was not performed. We considered the evidence-based interventions found in our review and developed a virtual service delivery model for HIV prevention interventions. We also considered how this platform could be leveraged for COVID-19 prevention and care. Results: We summarize 19 studies of virtual service delivery of PrEP and 16 relevant reviews. Examples of technology-based interventions that were effective, feasible, and/or acceptable for PrEP service delivery include: use of SMS, internet, and smartphone apps such as iText (50% [95% CI 16%-71%] reduction in discontinuation of PrEP) and PrEPmate (OR 2.62, 95% CI 1.24-5.5.4); telehealth and eHealth platforms for virtual visits such as PrEPTECH and IowaTelePrEP; and platforms for training of health care workers such as Extension for Community Healthcare Outcomes (ECHO). We suggest a virtual service delivery model for PrEP that can be leveraged for COVID-19 using the internet and social media for demand creation, community-based self-testing, telehealth platforms for risk assessment and follow-up, applications for support groups and adherence/appointment reminders, and applications for monitoring. Conclusions: Innovations in the virtual service provision of PrEP occurred before COVID-19 but have new relevance during the COVID-19 pandemic. The innovations we describe might strengthen HIV prevention service delivery during the COVID-19 pandemic and in the long run by engaging traditionally hard-to-reach populations, reducing stigma, and creating a more accessible health care platform. These virtual service delivery platforms can mitigate the impacts of the COVID-19 pandemic on HIV services, which can be leveraged to facilitate COVID-19 pandemic control now and for future responses.
- Open Access
- 1 April 2022
- Published by American Public Health Association in American Journal of Public Health
- Vol. 112 (4) , 562-563
Is Omicron Showing Us the Path Ahead?
- 1 April 2022
- Published by American Public Health Association in American Journal of Public Health
- Vol. 112 (4) , 562-563
Open AccessIs Omicron Showing Us the Path Ahead?